WO2003072731A3 - Particules chimeres hbc stabilisees ayant des immunogenes meningoques - Google Patents

Particules chimeres hbc stabilisees ayant des immunogenes meningoques Download PDF

Info

Publication number
WO2003072731A3
WO2003072731A3 PCT/US2003/005499 US0305499W WO03072731A3 WO 2003072731 A3 WO2003072731 A3 WO 2003072731A3 US 0305499 W US0305499 W US 0305499W WO 03072731 A3 WO03072731 A3 WO 03072731A3
Authority
WO
WIPO (PCT)
Prior art keywords
meningococcal
meningoccocal
immunogens
hbc chimer
hbc
Prior art date
Application number
PCT/US2003/005499
Other languages
English (en)
Other versions
WO2003072731A2 (fr
Inventor
Ashley J Birkett
Birgit Peck
Original Assignee
Apovia Inc
Ashley J Birkett
Birgit Peck
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apovia Inc, Ashley J Birkett, Birgit Peck filed Critical Apovia Inc
Priority to AU2003215395A priority Critical patent/AU2003215395A1/en
Publication of WO2003072731A2 publication Critical patent/WO2003072731A2/fr
Publication of WO2003072731A3 publication Critical patent/WO2003072731A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne une protéine nucléocapside du virus de l'hépatite B (HBc) tronquée, chimère et à terminaison carboxy contenant un immunogène d'induction de la production d'anticorps sur des protéines méningocoques. Un épitope méningocoque immunogène est exprimé entre les résidus 76 et 85 de la séquence en boucle immunogène HBc. Le chimère contient de préférence un épitope de lymphocyte T spécifique au méningocoque et comprend un résidu de cystéine à terminaison C assurant une meilleure stabilité des particules chimères assemblées automatiquement. Font également l'objet de cette invention, les procédés d'obtention et d'utilisation des chimères.
PCT/US2003/005499 2002-02-21 2003-02-21 Particules chimeres hbc stabilisees ayant des immunogenes meningoques WO2003072731A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003215395A AU2003215395A1 (en) 2002-02-21 2003-02-21 STABILIZED HBc CHIMER PARTICLES HAVING MENINGOCCOCAL IMMUNOGENS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35861802P 2002-02-21 2002-02-21
US60/358,618 2002-02-21

Publications (2)

Publication Number Publication Date
WO2003072731A2 WO2003072731A2 (fr) 2003-09-04
WO2003072731A3 true WO2003072731A3 (fr) 2005-02-10

Family

ID=27765969

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/005499 WO2003072731A2 (fr) 2002-02-21 2003-02-21 Particules chimeres hbc stabilisees ayant des immunogenes meningoques

Country Status (2)

Country Link
AU (1) AU2003215395A1 (fr)
WO (1) WO2003072731A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883169B2 (en) 2007-08-16 2014-11-11 Chrontech Pharma Ab Immunogen platform

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2059256T3 (pl) 2006-08-11 2017-02-28 Life Sciences Research Partners Vzw Immunogenne peptydy i ich zastosowanie w zaburzeniach immunologicznych
CA2715611C (fr) 2008-02-14 2018-03-13 Life Sciences Research Partners Vzw Immunotherapie ciblant des agents pathogenes intracellulaires
ES2676630T3 (es) 2008-02-14 2018-07-23 Life Sciences Research Partners Vzw Control inmunogénico de tumores y células tumorales
JP5667062B2 (ja) 2008-10-10 2015-02-12 エラ、ビオテック、ソシエダッド、アノニマＥｒａ Ｂｉｏｔｅｃｈ， Ｓ．Ａ． 免疫原特異的アジュバントとしての組換えタンパク粒
EP2418284A1 (fr) 2010-08-13 2012-02-15 ERA Biotech, S.A. Séquences de polypeptides induisant le corps protéiques
ES2924027T3 (es) 2010-11-25 2022-10-04 Imcyse Sa Péptidos inmunogénicos para su uso en la prevención y/o tratamiento de enfermedades infecciosas, enfermedades autoinmunitarias, respuestas inmunitarias a alofactores, enfermedades alérgicas, tumores, rechazo de injerto y respuestas inmunitarias contra vectores virales usados para terapia génica o vacunación génica
GB201201511D0 (en) * 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
CA2995771A1 (fr) 2015-09-25 2017-03-30 Imcyse Sa Procedes et composes ameliores pour supprimer des reponses immunitaires a des agents therapeutiques
KR20220132023A (ko) 2016-04-19 2022-09-29 임시스 에스에이 신규 면역원성 CD1d 결합 펩티드

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0399743A1 (fr) * 1989-05-25 1990-11-28 Beecham Group Plc Dérivées de phosphonométhylthio-alkoxypurines, produits intermédiaires pour leurs préparation et composition pharmaceutiques les contenants
WO1999040934A1 (fr) * 1998-02-12 1999-08-19 Immune Complex, Corporation Proteines noyaux de l'hepatite b strategiquement modifiees et leurs derives
WO2001098333A2 (fr) * 2000-06-22 2001-12-27 Celltech Pharmaceuticals Limited Modification de l'antigene capsidique de l'hepatite b

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0399743A1 (fr) * 1989-05-25 1990-11-28 Beecham Group Plc Dérivées de phosphonométhylthio-alkoxypurines, produits intermédiaires pour leurs préparation et composition pharmaceutiques les contenants
WO1999040934A1 (fr) * 1998-02-12 1999-08-19 Immune Complex, Corporation Proteines noyaux de l'hepatite b strategiquement modifiees et leurs derives
WO2001098333A2 (fr) * 2000-06-22 2001-12-27 Celltech Pharmaceuticals Limited Modification de l'antigene capsidique de l'hepatite b

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
MCGUINNESS B ET AL: "Deduced Amino Acid Sequences of Class 1 Protein (PorA) from Three Strains of Neisseria Meningitidis: Synthetic Peptides Define the Epitopes Responsible for Serosubtype Specificity", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 171, no. 6, June 1990 (1990-06-01), pages 1871 - 1882, XP002904209 *
PUMPENS ET AL: "Hepatitis B Virus Core Particles as Epitope Carriers", INTERVIROLOGY, vol. 38, no. 1-2, 1995, pages 63 - 74, XP002903139 *
SCHODEL ET AL: "The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity", JOURNAL OF VIROLOGY, vol. 66, no. 1, January 1992 (1992-01-01), pages 106 - 114, XP002090146 *
VAN DER LEY P ET AL: "Use of Transformation To Construct Antigenic Hybrids of the Class 1 Outer Membrane Protein in Neisseria meningitidis", INFECTION AND IMMUNITY, vol. 61, no. 10, October 1993 (1993-10-01), pages 4217 - 4224, XP002904208 *
WIERTZ ET AL: "Identification of T Cell Epitopes Occuring in a Meningococcal Class 1 Outer Membrane Protein Using Overlapping Peptides Assembeld wih Simultaneous Multiple Peptide Synthesis", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 176, July 1992 (1992-07-01), pages 79 - 88, XP002266481 *
WIERTZ ET AL: "T-cell responses to outer membrane proteins of Neisseria meningitidis: comparative study of the Opa, Opc, and PorA proteins", INFECTION AND IMMUNITY, vol. 64, no. 1, January 1996 (1996-01-01), pages 298 - 304, XP002127427 *
ZLOTNICK ET AL: "Localization of the C terminus of the assembly domain of hepapatitis B virus capsid protein: Implications for morphogenesis and organization of encapsidated RNA", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 94, no. 18, September 1997 (1997-09-01), USA, pages 9556 - 6561, XP002982400 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883169B2 (en) 2007-08-16 2014-11-11 Chrontech Pharma Ab Immunogen platform

Also Published As

Publication number Publication date
AU2003215395A8 (en) 2003-09-09
WO2003072731A2 (fr) 2003-09-04
AU2003215395A1 (en) 2003-09-09

Similar Documents

Publication Publication Date Title
WO2002013765A3 (fr) Immunogene et vaccin antipaludeens
WO2005055957A3 (fr) Immunogene et vaccin contre la grippe
WO2002014478A3 (fr) Particules chimeriques immunogenes de hbc presentant une stabilite amelioree
WO2003072731A3 (fr) Particules chimeres hbc stabilisees ayant des immunogenes meningoques
WO2004075836A3 (fr) Particules chimeriques de hbc stabilisees en tant que vaccins therapeutique pour l'hepatite chronique
JP2005270111A (ja) パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
EP0992580A3 (fr) Epitopes de lymphocytes T humains immunodominants du virus de l'hépatite C
WO2001098333A3 (fr) Modification de l'antigene capsidique de l'hepatite b
WO1993000365A3 (fr) Polypeptides utilises dans la lutte contre le virus de l'hepatite c
EP0271302A3 (fr) Epitopes de la protéine de la nucléocapside du virus de l'hépatite B, pour cellules T
WO2004053091A3 (fr) Particules stabilisees de chimeres de hbc immunogenes
HK1081207A1 (en) Hbv precore protein capable of forming particles
WO2004048402A3 (fr) Gene de fusion ns3/4a non structurel a codons optimises du virus de l'hepatite c
WO1999050424A3 (fr) Preparation et utilisation d'antigenes
WO2003102165A3 (fr) Particules chimeriques hbc immunogenes stabilisees avec une cysteine d'extremite n-termnale
SI1506222T1 (sl) Himerni L1-proteini humanega papilomavirusa 16, ki obsegajo L2-peptid, delci, podobni virusu, pripravljeni iz njih, in postopek za pripravo delcev
EP0572737A3 (fr) Antigène fusion gag-env de HIV.
WO2001070262A3 (fr) Procede servant a generer des immunogenes elicitant des anticorps de neutralisation contre des zones de fusion active de proteines d'enveloppe de vih
EP0199480A3 (en) Hepatitis a virus vaccines
WO2002088339A3 (fr) Particules pseudovirales de birnavirus
WO1997039029A3 (fr) Epitope antigenique du determinant a de l'antigene de surface de l'hepatite b et ses utilisations
WO2003072722A3 (fr) Particules chimeres de la proteine capsidique de l'hepatite b aviaire immunogenique a stabilite amelioree
AU2001286669A1 (en) Oral fluid rapid assay for hepatitis c virus (hcv) antibodies using non-antibody labeling of iga molecules recognizing hcv peptide epitopes
IL160286A0 (en) Angiotensin peptide-carrier conjugates and uses thereof
WO2002026943A3 (fr) Production de particules pseudovirales de vhc en cellules d'insectes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP